Physician profile
Adam Baker
NPI 1316955578
$6,980.48
in general payments reported to CMS, 2019-2025
33 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $688 · 2021: $923 · 2022: $1,010 · 2023: $1,336 · 2024: $1,630 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,302 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.28 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,272.93 | 2019-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $674.60 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $608.31 | 2019-2025 | |
| Pfizer INC. | $545.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $362.63 | 2019-2025 | Aklief, Oracea, Epsolay |
| Lilly USA, LLC | $356.15 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $307.15 | 2020-2025 | |
| Dermavant Sciences, INC. | $252.72 | 2022-2024 | Vtama |
| Genzyme Corporation | $225.53 | 2021-2025 | |
| Leo Pharma INC. | $207.05 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $160.54 | 2021-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Incyte Corporation | $96.08 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $83.60 | 2022-2025 | Dupixent |
| Sandoz INC. | $79.72 | 2020-2024 | Hyrimoz |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.18 | 2022-2025 | Sotyktu |
| Allergan, INC. | $67.96 | 2019-2022 | |
| Dermira, INC. | $51.33 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.77 | 2022 | |
| Biofrontera INC. | $43.70 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $39.97 | 2023 | Klisyri |
| Verrica Pharmaceuticals INC. | $36.44 | 2024 | Ycanth |
| Encore Dermatology INC. | $34.87 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $34.18 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $33.40 | 2021 | |
| Bard Peripheral Vascular, INC. | $28.41 | 2023 | Jamshidi |
| Nabriva Therapeutics, Plc | $27.25 | 2022 | |
| Journey Medical Corporation | $25.36 | 2022-2025 | |
| Organon LLC | $24.86 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2024 | Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.26 | 2024 | Jublia, Arazlo |
| Antares Pharma, INC. | $19.49 | 2022 | |
| Mayne Pharma Commercial LLC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.